PATTIES FOODS (F:PH4) — Market Cap & Net Worth
Market Cap & Net Worth: PATTIES FOODS (PH4)
PATTIES FOODS (F:PH4) has a market capitalization of $1.44 Billion (€1.23 Billion) as of May 22, 2026. Listed on the F stock exchange, this Germany-based company holds position #7585 globally and #1036 in its home market, demonstrating a 1.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PATTIES FOODS's stock price €0.84 by its total outstanding shares 1598199929 (1.60 Billion). Analyse PH4 cash flow metrics to see how efficiently the company converts income to cash.
PATTIES FOODS Market Cap History: 2025 to 2026
PATTIES FOODS's market capitalization history from 2025 to 2026. Data shows growth from $1.07 Billion to $1.58 Billion (0.00% CAGR).
PATTIES FOODS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PATTIES FOODS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.95x
PATTIES FOODS's market cap is 3.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $1.07 Billion | $269.58 Million | -$437.00 Million | 3.95x | N/A |
Competitor Companies of PH4 by Market Capitalization
Companies near PATTIES FOODS in the global market cap rankings as of May 22, 2026.
Key companies related to PATTIES FOODS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.03 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #414 globally with a market cap of $66.20 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #577 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #598 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.03 Billion | $433.54 |
| #414 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.20 Billion | $642.59 |
| #577 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #598 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
PATTIES FOODS Historical Marketcap From 2025 to 2026
Between 2025 and today, PATTIES FOODS's market cap moved from $1.07 Billion to $ 1.58 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.58 Billion | +48.00% |
| 2025 | €1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of PATTIES FOODS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.44 Billion USD |
| MoneyControl | $1.44 Billion USD |
| MarketWatch | $1.44 Billion USD |
| marketcap.company | $1.44 Billion USD |
| Reuters | $1.44 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PATTIES FOODS
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more